These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 22807098)

  • 41. Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience.
    Fischell TA; Ebner A; Gallo S; Ikeno F; Minarsch L; Vega F; Haratani N; Ghazarossian VE
    JACC Cardiovasc Interv; 2016 Mar; 9(6):589-98. PubMed ID: 27013159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Renal artery denervation for treating refractory hypertension].
    Benamer H; Louvard Y; Garot P; Unterseeh T; Hovasse T; Lefèvre T; Chevalier B; Morice MC
    Ann Cardiol Angeiol (Paris); 2011 Dec; 60(6):354-60. PubMed ID: 22040858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.
    Böhm M; Mahfoud F; Ukena C; Hoppe UC; Narkiewicz K; Negoita M; Ruilope L; Schlaich MP; Schmieder RE; Whitbourn R; Williams B; Zeymer U; Zirlik A; Mancia G;
    Hypertension; 2015 Apr; 65(4):766-74. PubMed ID: 25691618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Follow-up, study design and outcome parameters.
    Volpe M; Battistoni A; Tocci G
    EuroIntervention; 2013 May; 9 Suppl R():R96-100. PubMed ID: 23732163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects.
    Kjeldsen SE; Os I; Mahfoud F
    EuroIntervention; 2013 May; 9 Suppl R():R7-9. PubMed ID: 23732159
    [No Abstract]   [Full Text] [Related]  

  • 48. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of pseudo-resistance on the effect of renal denervation on 24-hour ambulatory blood pressure levels.
    Lambert T; Nahler A; Reiter C; Gammer V; Blessberger H; Kammler J; Grund M; Saleh K; Schwarz S; Steinwender C
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):E126-30. PubMed ID: 26033366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renal denervation: unde venis et quo vadis?
    Nähle CP; Düsing R; Schild H
    Rofo; 2015 Apr; 187(4):237-47. PubMed ID: 25629384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
    Krum H; Schlaich M; Whitbourn R; Sobotka PA; Sadowski J; Bartus K; Kapelak B; Walton A; Sievert H; Thambar S; Abraham WT; Esler M
    Lancet; 2009 Apr; 373(9671):1275-81. PubMed ID: 19332353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study.
    Tsioufis C; Papademetriou V; Tsiachris D; Kasiakogias A; Kordalis A; Thomopoulos C; Dimitriadis K; Tousoulis D; Stefanadis C; Parati G; Worthley S
    Int J Cardiol; 2015 Feb; 180():237-42. PubMed ID: 25463375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.
    de Jager RL; de Beus E; Beeftink MM; Sanders MF; Vonken EJ; Voskuil M; van Maarseveen EM; Bots ML; Blankestijn PJ;
    Hypertension; 2017 Apr; 69(4):678-684. PubMed ID: 28264922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility of catheter ablation renal denervation in "mild" resistant hypertension.
    Chen S; Kiuchi MG; Acou WJ; Derndorfer M; Wang J; Li R; Kollias G; Martinek M; Kiuchi T; Pürerfellner H; Liu S
    J Clin Hypertens (Greenwich); 2017 Apr; 19(4):361-368. PubMed ID: 28266770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of two different renal denervation strategies on blood pressure in resistant hypertension: Comparison of full-length versus proximal renal artery ablation.
    Chen W; Ling Z; Du H; Song W; Xu Y; Liu Z; Su L; Xiao P; Yuan Y; Lu J; Zhang J; Li Z; Shao J; Zhong B; Zhou B; Woo K; Yin Y
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):786-795. PubMed ID: 27219520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension.
    Ezzahti M; Moelker A; Friesema EC; van der Linde NA; Krestin GP; van den Meiracker AH
    J Hypertens; 2014 Jan; 32(1):135-41. PubMed ID: 24131897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of blood pressure response: Obesity is associated with a less pronounced treatment response after renal denervation.
    Id D; Bertog SC; Ziegler AK; Hornung M; Hofmann I; Vaskelyte L; Matic P; Gafoor S; Sievert H
    Catheter Cardiovasc Interv; 2016 Jan; 87(1):E30-8. PubMed ID: 26104216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Endovascular radiofrequency denervation of renal arteries as an innovation method of treatment of refractory arterial hypertension. First experience in Russia].
    Danilov NM; Matchin IuG; Chazova IE
    Angiol Sosud Khir; 2012; 18(1):51-4. PubMed ID: 22836328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term follow-up after radio-frequency catheter-based denervation in patients with resistant hypertension.
    Skowerski M; Roleder T; Bańska-Kisiel K; Pysz P; Ochała A; Wojakowski W; Gąsior Z
    Int J Cardiol; 2016 Jul; 215():472-5. PubMed ID: 27131767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry.
    Vogel B; Kirchberger M; Zeier M; Stoll F; Meder B; Saure D; Andrassy M; Mueller OJ; Hardt S; Schwenger V; Strothmeyer A; Katus HA; Blessing E
    Clin Res Cardiol; 2014 Feb; 103(2):117-24. PubMed ID: 24126436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.